Abstract
2/2021
vol. 17
Image in intervention
Long-term benefit of redo sympathetic renal denervation in a patient with resistant hypertension
- Department of Cardiology and Cardiovascular Interventions, University Hospital, Krakow, Poland
- Department of Intensive Care and Perioperative Medicine, Jagiellonian University Medical College, Krakow, Poland
Adv Interv Cardiol 2021; 17, 2 (64): 239–241
Online publish date: 2021/07/09
Sympathetic renal denervation (RDN) has been demonstrated as a potential treatment option for patients with resistant hypertension [1]. Despite discouraging results after the SYMPLICITY HTN-3 trial several techniques and catheters were introduced to the market and data confirming adequate and effective denervation are growing [1, 2]. In current guidelines invasive methods are not recommended as routine treatment of resistant hypertension [3, 4]. However, a highly selected group of patients not responding to aggressive medical treatment might benefit from this method [1–4].
Indexed in
Integrated with
